





## ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18  
Stylesheet Version v18.0

<b>Title of Invention</b>	<b>Cancerous disease modifying antibodies</b>																																																																																												
<p>Application Number: 10/603006 </p> <p>Confirmation Number: 1649</p> <p>First Named Applicant: David Young</p> <p>Attorney Docket Number: 2056.023</p> <p>Art Unit: 1641</p> <p>Search string: ( 5750102 or 4861581 or 5171665 or 5484596 or 5693763 or 5783186 or 5849876 or 5869268 or 5869045 or 5780033 ).pn.</p> <p><b>US Patent Documents</b></p> <p>Note: Applicant is not required to submit a paper copy of cited US Patent Documents</p> <table border="1"><thead><tr><th>init</th><th>Cite.No.</th><th>Patent No.</th><th>Date</th><th>Patentee</th><th>Kind</th><th>Class</th><th>Subclass</th></tr></thead><tbody><tr><td>PR</td><td>1</td><td>5750102</td><td>1998-05-12</td><td>Eisenbach et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>2</td><td>4861581</td><td>1989-08-29</td><td>Epstein et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>3</td><td>5171665</td><td>1992-12-15</td><td>Hellstrom et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>4</td><td>5484596</td><td>1996-01-16</td><td>Hanna, Jr. et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>5</td><td>5693763</td><td>1997-12-02</td><td>Codington et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>6</td><td>5783186</td><td>1998-07-21</td><td>Arakawa et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>7</td><td>5849876</td><td>1998-12-15</td><td>Linsley et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>8</td><td>5869268</td><td>1999-02-09</td><td>Kudo et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>9</td><td>5869045</td><td>1999-02-09</td><td>Hellstrom et al</td><td></td><td></td><td></td></tr><tr><td>PR</td><td>10</td><td>5780033</td><td>1998-07-14</td><td>Torchilin et al</td><td></td><td></td><td></td></tr></tbody></table> <p><b>Signature</b></p> <table border="1"><tr><td><b>Examiner Name</b></td><td><b>Date</b></td></tr><tr><td>/Peter Reddig/</td><td>07/05/2006</td></tr></table>		init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass	PR	1	5750102	1998-05-12	Eisenbach et al				PR	2	4861581	1989-08-29	Epstein et al				PR	3	5171665	1992-12-15	Hellstrom et al				PR	4	5484596	1996-01-16	Hanna, Jr. et al				PR	5	5693763	1997-12-02	Codington et al				PR	6	5783186	1998-07-21	Arakawa et al				PR	7	5849876	1998-12-15	Linsley et al				PR	8	5869268	1999-02-09	Kudo et al				PR	9	5869045	1999-02-09	Hellstrom et al				PR	10	5780033	1998-07-14	Torchilin et al				<b>Examiner Name</b>	<b>Date</b>	/Peter Reddig/	07/05/2006
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass																																																																																						
PR	1	5750102	1998-05-12	Eisenbach et al																																																																																									
PR	2	4861581	1989-08-29	Epstein et al																																																																																									
PR	3	5171665	1992-12-15	Hellstrom et al																																																																																									
PR	4	5484596	1996-01-16	Hanna, Jr. et al																																																																																									
PR	5	5693763	1997-12-02	Codington et al																																																																																									
PR	6	5783186	1998-07-21	Arakawa et al																																																																																									
PR	7	5849876	1998-12-15	Linsley et al																																																																																									
PR	8	5869268	1999-02-09	Kudo et al																																																																																									
PR	9	5869045	1999-02-09	Hellstrom et al																																																																																									
PR	10	5780033	1998-07-14	Torchilin et al																																																																																									
<b>Examiner Name</b>	<b>Date</b>																																																																																												
/Peter Reddig/	07/05/2006																																																																																												



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/603,006
				Filing Date	06/23/2003
				First Named Inventor	David S. F. Young
				Art Unit	1641
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	2056.023

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PR		T. KARPANEN et al, "Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth", Cancer Research, 61:1786-1790 (March, 2001)	
PR		W. WAUD et al, "Characterization of in vivo mammary and prostate tumor xenograft models for growth and response to clinical anticancer agents", Contrib Oncol Basel Karger, 54:305-315 (1999)	
PR		G. KLEMENT et al, "Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts", Clinical Cancer Research, 8:221-232 (January, 2002)	
PR		D. BLAKEY et al, "Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models", Clinical Cancer Research, 8:1974-1983 (June, 2002)	
PR		Z. XIAO et al, "Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay", Protein Expression and Purification, 19:12-21 (2000)	
PR		S. Guichard et al, "Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation", Clinical Cancer Research, 7:3222-3228 (October, 2001)	
PR		V. VON GRUENIGEN et al, "Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer", Int. J. Gynecol. Cancer, 9:365-372 (1999)	
PR		N. GUILBAUD et al, "Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors", Clinical Cancer Research, 7:2573-2580 (August, 2001)	
PR		K. OLSON et al, "Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody", Int. J. Cancer, 98:923-929 (2002)	
PR		S. HIRSCHFELD et al, "Oncology drug development: United States Food and Drug Administration perspective", Critical Reviews in Oncology/Hematology, 42:137-143 (2002)	

Examiner Signature	/Peter Reddig/	Date Considered	07/05/2006
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete If Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>Application Number</b>		10/603,006		
	<b>Filing Date</b>		06/23/2003		
	<b>First Named Inventor</b>		David S. F. Young		
	<b>Art Unit</b>		1641		
	<b>Examiner Name</b>				
<b>Sheet</b>	2	of	2	<b>Attorney Docket Number</b>	2056.023

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PR		P. THERASSE et al, "New guidelines to evaluate the response to treatment in solid tumors", Journal of the National Cancer Institute. 92(3):205-216 (February, 2000)	
PR		G. ECKHARDT et al, "Developmental therapeutics: successes and failures of clinical trial designs of targeted compounds", in American Society of Clinical Oncology, pp. 209-219 (2003)	
PR		P. SMITH et al, "Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice", The Prostate, 48:47-53 (2001)	

<b>Examiner Signature</b>	/Peter Reddig/	<b>Date Considered</b>	07/05/2006
---------------------------	----------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.